(Q40330261)

19 September 2017

title

Phase 1/2 trial of autologous tumor mixed with an allogeneic GVAX vaccine in advanced-stage non-small-cell lung cancer (English)

1 reference

19 September 2017

main subject

phase I clinical trial

0 references

phase II clinical trial

0 references

author name string

J Nemunaitis

1

1 reference

19 September 2017

T Jahan

2

1 reference

19 September 2017

H Ross

3

1 reference

19 September 2017

D Sterman

4

1 reference

19 September 2017

D Richards

5

1 reference

19 September 2017

B Fox

6

1 reference

19 September 2017

D Jablons

7

1 reference

19 September 2017

J Aimi

8

1 reference

19 September 2017

A Lin

9

1 reference

19 September 2017

K Hege

10

1 reference

19 September 2017

publication date

1 June 2006

1 reference

19 September 2017

1 reference

19 September 2017

volume

13

1 reference

19 September 2017

issue

6

1 reference

19 September 2017

page(s)

555-562

1 reference

https://scigraph.springernature.com/pub.10.1038/sj.cgt.7700922

19 September 2017

exact match

0 references

cites work

Vaccination with irradiated tumor cells engineered to secrete murine granulocyte-macrophage colony-stimulating factor stimulates potent, specific, and long-lasting anti-tumor immunity

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7700922

Irradiated tumor cells adenovirally engineered to secrete granulocyte/macrophage-colony-stimulating factor establish antitumor immunity and eliminate pre-existing tumors in syngeneic mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7700922

Vaccination with irradiated, autologous melanoma cells engineered to secrete granulocyte-macrophage colony-stimulating factor by adenoviral-mediated gene transfer augments antitumor immunity in patients with metastatic melanoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7700922

Novel allogeneic granulocyte-macrophage colony-stimulating factor-secreting tumor vaccine for pancreatic cancer: a phase I trial of safety and immune activation

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7700922

Granulocyte-macrophage colony-stimulating factor gene-modified autologous tumor vaccines in non-small-cell lung cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7700922

A universal granulocyte-macrophage colony-stimulating factor-producing bystander cell line for use in the formulation of autologous tumor cell-based vaccines

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7700922

Clinical trials of antitumor vaccination with an autologous tumor cell vaccine modified by virus infection: improvement of patient survival based on improved antitumor immune memory

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7700922

Enhanced immunogenicity of BCG vaccine by using a viral-based GM-CSF transgene adjuvant formulation.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7700922

High-dose granulocyte-macrophage colony-stimulating factor-producing vaccines impair the immune response through the recruitment of myeloid suppressor cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7700922

Genetic immunotherapy of established tumors with adenovirus-murine granulocyte-macrophage colony-stimulating factor

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7700922

7 January 2021

Phase 1 clinical trial of irradiated autologous melanoma cells adenovirally transduced with human GM-CSF gene

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7700922

7 January 2021

Immunogenetic therapy of human melanoma utilizing autologous tumor cells transduced to secrete granulocyte-macrophage colony-stimulating factor

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7700922

7 January 2021

Vaccination with irradiated autologous tumor cells engineered to secrete granulocyte-macrophage colony-stimulating factor augments antitumor immunity in some patients with metastatic non-small-cell lung carcinoma

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7700922

7 January 2021

Southwest Oncology Group standard response criteria, endpoint definitions and toxicity criteria

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7700922

7 January 2021

Identifiers

DOI

10.1038/SJ.CGT.7700922

1 reference

Dimensions Publication ID

19 September 2017

1053424710

0 references

1 reference